A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

References

• Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch F, de Sanjosé S Human papillomavirus and related diseases in the world. Summary Report; 2017 July 27 [accessed 2018 Nov 22]. http://hpvcentre.net/statistics/reports/XWX.pdf.
   Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin H-R, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi:10.1016/S1470-2045(10)70230-8.
   PubMed Web of Science ®Google Scholar
• Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman CBJ. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. Br J Obstet Gynaecol. 2002;109(1):96–98. doi:10.1111/j.1471-0528.2002.01053.x.
   Google Scholar
• Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med. 2010;8:105.
   PubMed Web of Science ®Google Scholar
• Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191(2):182–92. doi:10.1086/426867.
   PubMed Web of Science ®Google Scholar
• Parry J. Vaccinating against cervical cancer. Bull World Health Organ. 2007;85:85–160.
   Web of Science ®Google Scholar
• Moscicki A-B. HPV infections in adolescents. Dis Markers. 2007;23:229–34. doi:10.1155/2007/136906.
   PubMed Web of Science ®Google Scholar
• Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow S-N, Kitchener HC, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015;22(4):361–73. doi:10.1128/CVI.00591-14.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA and Dubin G. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. The Lancet. 2006;367(9518):1247–55. doi:10.1016/S0140-6736(06)68439-0.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99. doi:10.1016/S1470-2045(11)70286-8.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• Szarewski A. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev Vaccines. 2012;11(6):645–57. doi:10.1586/erv.12.42.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow S-N, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10. doi:10.1016/S1470-2045(11)70287-X.
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin Immunother. 2014;10(8):2147–62. doi:10.4161/hv.29532.
   PubMed Web of Science ®Google Scholar
• Romanowski B, de Borba P, Naud P, Roteli-Martins C, De Carvalho N, Teixeira J, Aoki F, Ramjattan B, Shier R, Somani R, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. The Lancet. 2009;374(9706):1975–85. doi:10.1016/S0140-6736(09)61567-1.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Galaj A, Spaczynski M, Wysocki J, Kaufmann AM, Poncelet S, Suryakiran PV, Folschweiller N, Thomas F, Lin L, et al. Ten-year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age. Cancer Med. 2017;6(11):2723–31. doi:10.1002/cam4.1155.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Huang L-M, Lin T-Y, Wittermann C, Panzer F, Valencia A, Suryakiran PV, Lin L, Descamps D. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J. 2014;33(12):1255–61. doi:10.1097/INF.0000000000000460.
   PubMed Web of Science ®Google Scholar
• Rivera Medina DM, Valencia A, de Velasquez A, Huang L-M, Prymula R, García-Sicilia J, Rombo L, David MPP, Descamps D, Hardt K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health. 2010;46(5):414–21. doi:10.1016/j.jadohealth.2010.02.006.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Huang L-M, Medina DMR, Valencia A, Lin T-Y, Behre U, Catteau G, Thomas F, Descamps D. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 years. J Adolesc Health. 2012;50(2):187–94. doi:10.1016/j.jadohealth.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet. 2007;369(9580):2161–70. doi:10.1016/S0140-6736(07)60946-5.
   PubMed Web of Science ®Google Scholar
• Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer. 2011;129(9):2147–57. doi:10.1002/ijc.25887.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine. 2009;27(4):581–87. doi:10.1016/j.vaccine.2008.10.088.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. doi:10.1086/657321.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014;32(39):5087–97. doi:10.1016/j.vaccine.2014.06.038.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154–68. doi:10.1016/S1473-3099(16)30120-7.
   PubMed Web of Science ®Google Scholar
• Folschweiller N, on behalf of the HPV-070 and HPV-048 study groups. Cross-reactive immunogenicity of the AS04-adjuvanted HPV-16/18 vaccine given as a 2-dose schedule in girls aged 9–14 years vs 3-dose in women 15–25 years. European Society for Paediatric Infectious Diseases - 36th Annual Meeting. Malmö (Sweden); 2018 [accessed 2018 Dec 18]. https://2018.espidmeeting.org/2018/PublishingImages/abstract-information/espid-abstracts/ESPID18%20all%20Abstracts.pdf.
   Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293–302. doi:10.1016/S1473-3099(17)30468-1.
   PubMed Web of Science ®Google Scholar
• Woestenberg PJ, King AJ, van Benthem BHB, Donken R, Leussink S, van der Klis FRM, de Melker HE, van der Sande MAB, Hoebe CJPA, Bogaards JA, et al. Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. J Infect Dis. 2018;217(2):213–22. doi:10.1093/infdis/jix582.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012;31(1):234–41. doi:10.1016/j.vaccine.2012.09.037.
   PubMed Web of Science ®Google Scholar
• Egbe A, Uppu S, Lee S, Stroustrup A, Ho D, Srivastava S. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. Pediatr Neonatol. 2015;56(1):25–30. doi:10.1016/j.pedneo.2014.03.010.
   PubMed Web of Science ®Google Scholar
• Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B, Rossier C, Gerdts C, Tunçalp Ö, Johnson BR Jr., et al. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. The Lancet. 2016;388(10041):258–67. doi:10.1016/S0140-6736(16)30380-4.
   PubMed Web of Science ®Google Scholar
• Dulay AT. Spontaneous abortion; 2018 [accessed 2018 Aug 13]. https://www.merckmanuals.com/en-ca/professional/gynecology-and-obstetrics/abnormalities-of-pregnancy/spontaneous-abortion.
   Google Scholar
• Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, Flenady V, Frøen JF, Qureshi ZU, Calderwood C, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. The Lancet. 2016;387(10018):587–603. doi:10.1016/S0140-6736(15)00837-5.
   PubMed Web of Science ®Google Scholar
• Tay JI, Moore J, Walker JJ. Ectopic pregnancy. West J Med. 2000;173(2):131–34. doi:10.1136/ewjm.173.2.131.
   PubMedGoogle Scholar
• López-Fauqued M, Zima J, Angelo M-G, Stegmann J-U. Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. Vaccine. 2017;35(40):5325–30. doi:10.1016/j.vaccine.2017.08.042.
   PubMed Web of Science ®Google Scholar
• Baril L, Rosillon D, Willame C, Angelo MG, Zima J, van Den Bosch JH, Van Staa T, Boggon R, Bunge EM, Hernandez-Diaz S, et al. Risk of spontaneous abortion and other pregnancy outcomes in 15–25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine. 2015;33(48):6884–91. doi:10.1016/j.vaccine.2015.07.024.
   PubMed Web of Science ®Google Scholar
• Angelo M-G, David M-P, Zima J, Baril L, Dubin G, Arellano F, Struyf F. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 2014;23(5):466–79. doi:10.1002/pds.3554.
   PubMed Web of Science ®Google Scholar
• Angelo M-G, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf. 2014;23(5):456–65. doi:10.1002/pds.3593.
   PubMed Web of Science ®Google Scholar
• Huang L-M, Puthanakit T, Cheng-Hsun C, Ren-Bin T, Schwarz T, Pellegrino A, Esposito S, Frenette L, McNeil S, Durando P, et al. Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9–14 years: a randomized trial. J Infect Dis. 2017;215(11):1711–19. doi:10.1093/infdis/jix154.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016;12(1):20–29. doi:10.1080/21645515.2015.1065363.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin Infect Dis. 2018;66(3):339–45. doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62. doi:10.4161/hv.29532.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA and Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4(6):425–34. doi:10.4161/hv.4.6.6912.
   PubMed Web of Science ®Google Scholar
• Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, Ferguson M, Hillemanns P, McNeil SA, Peters K, et al. Long-term cross-reactivity against nonvaccine human papillomavirus types 31 and 45 after 2- or 3-dose schedules of the AS04-adjuvanted human HPV-16/18 vaccine. J Infect Dis. 2019;219(11):1799–803. doi:10.1093/infdis/jiy743.
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716–23. doi:10.1109/TAC.1974.1100705.
   Web of Science ®Google Scholar